Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study

Table 4 PSA response rate, overall survival, and time-to-treatment failure

Outcome	C20		C25		Statistic
Outcome	N	Response rate, n (%)	N	Response rate, n (%)	OR (95% CI)	p
PSA response	601	169 (28.1)^b
Unadjusted	177	49 (27.7)	146	46 (31.5)	1.20 (0.74–1.94)	0.453
Multivariable^a	135	38 (28.2)	120	36 (30.0)	1.18 (0.66–2.13)	0.572
PSM	106	28 (26.4)	103	33 (32.0)	1.31 (0.72–2.39)	0.372
Outcome	N	Median (95% CI)	N	Median (95% CI)	HR (95% CI)	p
OS (days)	656	319 (293–361)^b
Unadjusted	188	287 (240–326)	159	NR	0.71 (0.53–0.97)	0.030
Multivariable^a	141	287 (234–327)	129	NR	0.69 (0.48–0.99)	0.047
PSM	110	291 (230–NR)	112	NR	0.73 (0.50–1.08)	0.119
TTF (days)	660	116 (108–135)^b
Unadjusted	190	113 (94–137)	159	120 (104–157)	0.78 (0.62–0.97)	0.026
Multivariable^a	143	115 (92–138)	129	115 (99–157)	0.71 (0.54–0.93)	0.014
PSM	112	122 (90–148)	112	120 (109–158)	0.75 (0.57–0.99)	0.046

C20 20 mg/m² cabazitaxel, C25 25 mg/m² cabazitaxel, PSA Prostate-specific antigen, OR Odds ratio, CI Confidence interval, PSM Propensity score matching, HR Hazard ratio, OS Overall survival, NR Not reached, TTF Time-to-treatment failure
^aCovariates were: age, body surface area, duration of disease, Gleason score, TNM, performance status, PSA, medical history, complications, curative intent focal therapy, palliative radiation therapy, and previous treatment (docetaxel, enzalutamide or abiraterone acetate)
^bIn all available patients

ISSN: 1471-2407